University of California

Other

State of Oregon

Oregon State University

University of Rhode Island Research Foundation

Genyous Biomed International Inc.

William H Gerwick

Robert S Jacobs

Philip J Proteau

Richard Castenholz

Ferran Garcia-Pichel

Frederick A Valeriote

Lisa A Marshall

Christopher Stevenson

James Rossi

Krista J Grace

Dennis A Carson

Wolfgang J Wrasidlo

John Russell Falck

Brian Kevin Paul

Goran Jovanovic

David C Rowley

Anthony J O'Donoghue

Bradley S Moore

Janine E Trempy

Jennifer Smith

Rebecca Ann Medina

Hyuakjae Choi

Francisco Villa

Wojtek Kolodziej

Phil McFadden

Thomas K Plant

Dwayne Stupack

Corwin Willard

Takashi Suyama

Frank W R Chaplen

Tara Byrum

Jim Liburdy

Michael Kenneth Gilson

Kevin Tidgewell

James Dao

Dale G Nagle

Andrew T Fenley

Tom C S Dao

David D Tong

Brian L Marquez

Jehad Almaliti

Leslie Wilson

Matthew W Bernart

Mary Ann Jordan

Andrew Kale

Kerry Leigh McPhail

Hosana Debonsi

Douglas Eugene Goeger

Betsaida Bibo Verdugo

Alban R Pereira-Badilla

Lena Gerwick

Todd Leo Capeon

Methods and pharmaceutical compositions for treating malaria and immune related disorders are provided. The pharmaceutical compositions include an effective amount a carmaphycin B analog that inhibits immunoproteasome activity in a subject.

Immunoproteasome inhibitor

In particular, in alternative embodiments, the invention provides pharmaceutical compounds and formulations comprising a family of epoxyketone compounds, which include racemic mixtures or racemates, isomers, stereoisomers, diastereoisomers, derivatives and analogs, and methods for making and using them. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to treat, prevent, reverse and/or ameliorate an infection, disease or condition that can be ameliorated, treated, prevented or reversed by partially or completely inhibiting a chymotrypsin-like protease or a proteasome activity, including e.g., a retroviral infection such as human immunodeficiency virus-1 (HIV-1) infection, an immune disorder, a neurodegenerative disease or condition, or a cancer such as a myeloma or multiple myeloma, an adenocarcinoma such as a lung adenocarcinoma, a pancreatic cancer, a B-cell related cancer, and lymphomas such as non-Hodgkin's lymphoma.

Compositions and methods for inhibiting proteases

The invention provides novel compositions based on a structure designated as 'Honaucin A', including Honaucin A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used to ameliorate (including to treat or prevent) inflammation. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used to ameliorate (including to treat or prevent) inflammation. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used as bacterial quorumsensing inhibitors. Accordingly, in alternative embodiments the compositions of the invention are used as anti-bacterial agents.

Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using them

The invention provides novel compositions&#x2014;lipopeptides and analogs, including somocystinamide A, and somocystinamide A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these lipopeptides and analogs are used to induce apoptosis in a cell, which can be a normal cell, a dysfunctional cell and/or a cancer (tumor) cell. In alternative embodiments, the compositions of the invention, including the lipopeptides and analogs of the invention, and the pharmaceutical compositions comprising them, are used to treat or ameliorate (including slowing the progression of) normal, dysfunctional (e.g., abnormally proliferating) and/or tumor associated blood vessels, including endothelial and/or capillary cell growth; including neovasculature related to (within, providing a blood supply to) a tumor.

Methods for treating or ameliorating a melanoma and killing melanoma cells

In alternative embodiments, the invention provides apratoxin F and apratoxin G compounds, which include apratoxin F and apratoxin G stereoisomers, derivatives and analogs compositions and methods. In alternative embodiments, the invention provides pharmaceutical compositions and formulations comprising apratoxin F (compound 6 of FIG.) and apratoxin G (compound 7 of FIG.) and their stereoisomers, derivatives and analogs. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered in an amount sufficient to treat, prevent and/or ameliorate a disease or condition that can be ameliorated by decreasing or inhibiting cell growth, e.g., pathological, uncontrolled or unwanted cell growth, e.g., a cancer or a metastases, or any disease or condition (e.g., allergy) or infection having a hyperproliferative cell growth component.

Compositions for ameliorating cell proliferative disorders and methods of making and using them

Methods and compositions for prevention and therapy of cancer are provided. Compositions comprising therapeutically effective amounts of two or more of an extract of, an extract ofand an extract ofand optionally a therapeutically effective amount of an extract ofare provided. Novel synergistic effects of the use of these compounds in combination therapy are disclosed. Embodiments further comprising therapeutically effective amounts of at least one chemotherapeutic agent are also provided.

Compositions of botanical extracts for cancer therapy

Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.

Isolation, purification, and structure elucidation of the antiproliferative compound coibamide A

Methods of detecting bioactive compounds include exposing compounds to one or more classes of chromatophores and measuring or sensing associated changes in one or more of the chromatophores. Representative methods permit identification and quantification of neurotransmitters, toxins, hormones, and chemical warfare agents with or without prior knowledge of the content of a sample. In some examples, chromatophores based on Betta fish are used. Cytosensor apparatus using such chromatophores include means for exposing chromatophores to a sample and optical detection systems for assessing changes in chromatophore optical properties. Compounds can be identified or quantified based on a red-green-blue or hue saturation-value representations of transmitted or reflected light or based on other characterizations of transmitted or reflected light.

Methods for detecting bioactive compounds

Disclosed are compounds having a scytoneman skeleton, such as scytonemin, and methods of using thereof. Methods of using a compound having a scytoneman skeleton to inhibit, modulate, attenuate, or prevent cell-cycle progression, cell proliferation, kinase activity, or induce apoptosis are disclosed. Also disclosed are methods of treating, preventing, or inhibiting diseases and disorders associated with cell cycle progression, cell proliferation, kinase activity, tissue hyperplasia or angiogenesis, such as cancer or an inflammatory disease.

Scytonemin and methods of using thereof

Isomers of a cytotoxic compound isolated and purified from a marine cyanobacterium Lyngbya majuscula are disclosed. The compound, termed 'curacin D', exhibits substantial biological activity against proliferating cells. Analogs of curacin A also are described, as are formulations that include curacin D and the curacin A analogs. The curacins A-D and analogs of curacin A exhibit antimitotic behavior.

Curacin A analogs exhibiting antiproliferative activity against cells

Indole alkaloid compounds having the formula ##STR1## where R and R' are H, an alkyl group having up to 5 carbon atoms or --CO--(CH.sub.2).sub.n --CH.sub.3 where n=0 to 16. The indole alkaloid compounds and their reduction products are useful as both UV protective and anti-inflammatory agents.

Indole alkaloids useful as UV protective and anti-inflammatory agents

Anti-flammatory method using indole alkaloids

Isomers of a cytotoxic compound isolated and purified from a marine cyanobacterium Lyngbya majuscula are disclosed. The isomers termed Curacin A and Curacin B exhibits substantial biological activity against proliferating cells. The Curacin A and Curacin B isomers appear to be antimitotics. Methods for using the isomers are also disclosed.

Compound exhibiting antiproliferative activity against cells

Growing community of inventors

Corvallis, OR, United States of America

William H Gerwick